Találati lista | Tudóstér

001-es BibID:	BIBFORM051051
035-os BibID:	PMID:23588883
Első szerző:	Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:	Bone metabolism and the 10-year probability of hip fracture and a major osteoporotic fracture using the country-specific FRAX algorithm in men over 50 years of age with type 2 diabetes mellitus : a case-control study / Harjit P. Bhattoa, Ugo Onyeka, Edit Kalina, Adam Balogh, Gyorgy Paragh, Peter Antal-Szalmas, Miklos Kaplar
Dátum:	2013
ISSN:	0770-3198
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Egészség- és Környezettudomány
Megjelenés:	Clinical Rheumatology. - 32 : 8 (2013), p. 1161-1167. -
További szerzők:	Onyeka, Ugo Kalina Edit Balogh Ádám Paragh György (1953-) (belgyógyász) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Káplár Miklós (1965-) (belgyógyász, diabetológus)
Pályázati támogatás:	TÁMOP-4.2.1/B-09/1/KONV-2010-0007 TÁMOP Gyulladásos és egyéb proatherogén tényezők vizsgálata a lipidanyagcsere zavarával járó kórállapotokban OTKA 105073 OTKA
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM035327
Első szerző:	Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:	Bone mineral density in women with systemic lupus erythematosus / H. P. Bhattoa, P. Bettembuk, A. Balogh, G. Szegedi, E. Kiss
Dátum:	2002
ISSN:	0770-3198
Megjegyzések:	The aim of this cross-sectional study was to determine the prevalence of reduced bone mineral density (BMD) in a group of female SLE patients and to identify factors predictive of reduced BMD. Femoral neck (FN) and lumbar spine (LS) dual-energy X-ray absorptiometry results wer evaluated in 79 pre- and postmenopausal women with SLE aged (mean, range) 49 (22-73) years). Variables evaluated were disease duration, SLEDAI, current and cumulative corticosteroid dose, Steinbrocker's functional classification, use of immunosuppressive agents, and history of fracture due to minor trauma. A T-score of ?ë♯n 1.0 was found in 61.9% at the LS and 48.3% at the FN, and 18 (23.7%) patients belonged to the category of osteoporosis at LS, compared to only three (5.4%) patients at FN. A statistical difference (P = 0.014) was found when comparing LS BMD in pre- and postmenopausal patients. LS BMD had a significant correlation with daily and cumulative steroid dose (P = 0.016 and 0.031, respectively). There was a significant difference in LS BMD between the daily steroid dose group receiving ?ë♯n 7.5 and those receiving > 7.5. mg/day (P = 0.008), and also in FN BMD comparing groups on 0 and > 7.5 mg/day (P = 0.022). There was significant difference in LS and FN BMD between patients in Steinbrocker classes I and III (P = 0.016 and 0.005, respectively). No significant correlation was found in either subgroup between BMD and other studied parameters. We concluded that the prevalence of reduced bone mass at LS is pronounced among postmenopausal women with SLE, in those with a high Steinbrocker functional classification and those on a high daily steroid dose. Therefore, these patients should be considered as a high-risk group deserving regular spinal BMD scans and therapy in time to prevent vertebral fractures.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény Bone mineral density Female Glucocorticoids Osteoporosis Systemic lupus erythematosus corticosteroid immunosuppressive agent adult aged article bone density bone mass bone mineral bone scintiscanning controlled study correlation analysis disease classification disease duration dose response dual energy X ray absorptiometry female femur neck high risk patient human lumbar spine osteoporosis postmenopause prediction premenopause prevalence priority journal scoring system systemic lupus erythematosus vertebra fracture age distribution cohort analysis comparative study cross-sectional study hospitalization Hungary middle aged physiology probability radiodensitometry risk assessment risk factor Adrenal Cortex Hormones Adult Age Distribution Aged Bone Density Cohort Studies Comparative Study Cross-Sectional Studies Densitometry, X-Ray Female Human Hungary Lupus Erythematosus, Systemic Middle Age Osteoporosis Prevalence Probability Risk Assessment Risk Factors Severity of Illness Index Support, Non-U.S. Gov't Humans Middle Aged
Megjelenés:	Clinical Rheumatology. - 21 : 2 (2002), p. 135-141. -
További szerzők:	Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	Szerző által megadott URL Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM081053
035-os BibID:	(PMID)31522318
Első szerző:	Gulyás Katalin (reumatológus)
Cím:	Effects of 1-year anti-TNF-[alfa] therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis / Katalin Gulyás, Ágnes Horváth, Edit Végh, Anita Pusztai, Ágnes Szentpétery, Zsófia Pethö, Andrea Váncsa, Nóra Bodnár, Péter Csomor, Attila Hamar, Levente Bodoki, Harjit Pal Bhattoa, Balázs Juhász, Zoltán Nagy, Katalin Hodosi, Tamás Karosi, Oliver FitzGerald, Gabriella Szücs, Zoltán Szekanecz, Szilvia Szamosi, Sándor Szántó
Dátum:	2020
ISSN:	0770-3198
Megjegyzések:	OBJECTIVES: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with generalized and localized bone loss. We conducted a comprehensive study using imaging (dual-energy X-ray absorptiometry, DXA) and laboratory biomarkers in order to determine bone health and to study the effects of anti-tumor necrosis factor (TNF) biologics in RA and AS. PATIENTS AND METHODS: Thirty-six RA and 17 AS patients undergoing 1-year etanercept (ETN) or certolizumab-pegol (CZP) therapy were studied. Bone density was assessed by DXA at baseline and after 12 months. Serum C-reactive protein (CRP), calcium, phosphate, parathyroid hormone (PTH), vitamin D3, osteocalcin, procollagen type I N-propeptide (P1NP), C-terminal telopeptide (βCTX), osteoprotegerin, sclerostin (SOST), Dickkopf-1 (DKK-1), soluble receptor activator nuclear kappa B ligand (sRANKL), and cathepsin K (cathK) levels were determined at baseline and after 6 and 12 months. RESULTS: TNF-α inhibition was clinically effective. Anti-TNF-α halted further bone loss over 1 year. In general, anti-TNF therapy significantly increased P1NP, SOST levels, and the P1NP/βCTX ratios, while decreased DKK-1 and CathK production at different time points in most patient subsets. In the full cohort and in RA, baseline and/or 12-month bone mineral density (BMD) at multiple sites exerted inverse relationships with CRP and βCTX, and positive correlation with SOST. In AS, L2-4 BMD after 1-year biologic therapy inversely correlated with baseline βCTX, while femoral neck BMD rather showed inverse correlations with CRP. CONCLUSIONS: Anti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases. TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS. Key Points ? One-year anti-TNF therapy halted generalized bone loss in association with clinical improvement in arthritides. ? Anti-TNF therapy may inversely act on DKK-1 and SOST. ? Independent predictors of BMD were SOST and βCTX in RA, while CRP in AS.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Biologics Bone loss DKK-1 Erosion JAK inhibitors Osteoporosis Osteoprotegerin RANKL Rheumatoid arthritis Sclerostin Spondyloarthritis Syndesmophyte
Megjelenés:	Clinical Rheumatology. - 39 : 1 (2020), p. 167-175. -
További szerzők:	Horváth Ágnes (1985-) (reumatológus) Végh Edit (1978-) (reumatológus, belgyógyász) Karancsiné Pusztai Anita (1989-) (tudományos segédmunkatárs) Szentpétery Ágnes (1978-) (reumatológus) Pethő Zsófia (1981-) (reumatológus, immunológus) Váncsa Andrea (1972-) (orvos) Bodnár Nóra (1980-) (reumatológus) Csomor Péter (1984-) (biotechnológus) Hamar Attila Béla (1990-) (általános orvos) Bodoki Levente (1986-) (PhD hallgató) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Juhász Balázs (1973-) (orvos, onkológus) Nagy Zoltán (orvos) Hódosi Katalin Karosi Tamás (1979-) (fül-orr-gégész) FitzGerald, Oliver Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szántó Sándor (1968-) (belgyógyász, reumatológus)
Pályázati támogatás:	K 105073 OTKA TÁMOP-4.2.4.A/2-11/1-2012-0001 TÁMOP GINOP-2.3.2-15-2016-00015 GINOP GINOP-2.3.2-15-2016-00050 GINOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM072268
Első szerző:	Kardos Zsófia
Cím:	Increased frequency of temporal acoustic window failure in rheumatoid arthritis : a manifestation of altered bone metabolism? / Kardos Zsófia, Oláh Csaba, Sepsi Mariann, Sas Attila, Kostyál László, Bóta Tünde, Bhattoa Harjit Pal, Hodosi Katalin, Kerekes György, Tamási László, Bereczki Dániel, Szekanecz Zoltán
Dátum:	2018
ISSN:	0770-3198
Megjegyzések:	Assessment of intracranial vessels includes transcranial Doppler (TCD). TCD performance requires intact temporal acousticwindows (TAW). Failure of TAW (TAWF) is present in 8?20% of people. There have been no reports on TAWF in rheumatoidarthritis (RA). Altogether, 62 female RA patients were included. Among them, 20 were MTX-treated and biologic-free, 20received infliximab, and 22 tocilizumab. The controls included 60 non-RA women. TAWF, temporal bone thickness, and texturewere determined by ultrasound and CT. BMD and T-scores of multiple bones were determined by DEXA. Several bonebiomarkers were assessed by ELISA. In RA, 54.8% of the patients had TAWF on at least one side. Neither TAW could beidentified in 34% of RA subjects. In contrast, only 20.0% of control subjects had TAWF on either or both sides (p < 0.001). In RAvs controls, 53.0 vs 2.9% of subjects exerted the trilayer, Bsandwich-like^ structure of TAW (p < 0.001). Finally, in RA vscontrols, the mean temporal bone thickness values of the right TAW were 3.58 ? 1.43 vs 2.92 ? 1.22 mm (p = NS), while thoseof the left TAW were 4.16 ? 1.56 vs 2.90 ? 1.16 mm (p = 0.001). There was close association between TAWF, bone thickness,and texture (p < 0.05). These TAW parameters all correlated with age; however, TAW failure and texture also correlated withserum osteoprotegerin. TAW bone thickness inversely correlated with hip BMD (p < 0.05). TAWF, thicker, and heterogeneoustemporal bones were associated with RA. These features have been associated with bone loss and OPG production. Bone lossseen in RA may result in OPG release and stimulation of bone formation around TAW.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Biological therapy BMD Osteoporosis Osteoprotegerin Reumatoid arthritis Temporal acoustic window failure
Megjelenés:	Clinical Rheumatology. - 37 : 5 (2018), p. 1183-1188. -
További szerzők:	Oláh Csaba (1972-) (idegsebész) Sepsi Marianna Sas Attila Kostyál László (1974-) (radiológus) Bóta Tünde Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Hódosi Katalin Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Tamási László Bereczki Dániel (1960-) (neurológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: